NCT05062421

Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.

Persistence of Biological Treatment and Inhibitors of Jak Kinases in Habitual Clinical Practice in Patients With Rheumatoid Arthritis. Influence of the Comorbidities.

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 540 (estimated)
• Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.

Detailed description

One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). The drugs to be administered to patients are: * JAK-type kinase inhibitors. * Monoclonal antibodies against TNF. * Soluble receptor against TNF. * Biosimilar FAMEb. * Rituximab. * Abatacept. * Drugs that block IL6. A follow-up will be carried out at 12, 24, 48, 60, 72 and 84 months from the start of treatment, to analyze how the patient's health improves.

Conditions

• Arthritis, Rheumatoid

Timeline

• Start date: 2021-04-01
• Primary completion: 2026-12-01
• Completion: 2026-12-31
• First posted: 2021-09-30
• Last updated: 2021-11-17

Locations

1 site across 1 country: Spain